ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Antimicrobial Resistance (AMR) remains an existential threat to human health. Despite investment from public-private initiatives the development of new antimicrobials to meet the challenge of AMR remains extremely challenging. ESCMID is proud to host the 5th ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Dublin. This increasingly popular meeting is well attended by academics, regulators and funding agencies/ bodies. The meeting is focussed on the challenges of developing new agents for AMR that stretches from medicinal chemistry right through to the collective efforts of the international community to produce new antibiotics. If you are in the business of discovering and developing new drugs, you cannot miss this meeting.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.